HEADER TRANSFERASE/CELL CYCLE 02-OCT-12 4BCG TITLE STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4-HETEROARYL- TITLE 2 PYRIMIDINE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLIN-DEPENDENT KINASE 9; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 2-330; COMPND 5 SYNONYM: C-2K, CELL DIVISION CYCLE 2-LIKE PROTEIN KINASE 4, CELL COMPND 6 DIVISION PROTEIN KINASE 9, SERINE/THREONINE-PROTEIN KINASE PITALRE, COMPND 7 TAT-ASSOCIATED KINASE COMPLEX CATALYTIC SUBUNIT; COMPND 8 EC: 2.7.11.22, 2.7.11.23; COMPND 9 ENGINEERED: YES; COMPND 10 MOL_ID: 2; COMPND 11 MOLECULE: CYCLIN-T1; COMPND 12 CHAIN: B; COMPND 13 FRAGMENT: RESIDUES 2-259; COMPND 14 SYNONYM: CYCT1, CYCLIN-T; COMPND 15 ENGINEERED: YES; COMPND 16 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PVL1392; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 13 ORGANISM_COMMON: HUMAN; SOURCE 14 ORGANISM_TAXID: 9606; SOURCE 15 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 16 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 17 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 18 EXPRESSION_SYSTEM_STRAIN: SF9; SOURCE 19 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 20 EXPRESSION_SYSTEM_PLASMID: PVL1392 KEYWDS TRANSFERASE-CELL CYCLE COMPLEX, CDK-CYCLIN COMPLEX, TRANSCRIPTION- KEYWDS 2 PROTEIN BINDING, STRUCTURE-BASED DRUG DESIGN EXPDTA X-RAY DIFFRACTION AUTHOR A.J.HOLE,S.BAUMLI,S.WANG,J.A.ENDICOTT,M.E.M.NOBLE REVDAT 2 15-MAY-19 4BCG 1 REMARK LINK REVDAT 1 17-APR-13 4BCG 0 JRNL AUTH H.SHAO,S.SHI,S.HUANG,A.HOLE,A.Y.ABBAS,S.BAUMLI,X.LIU,F.LAM, JRNL AUTH 2 D.W.FOLEY,P.M.FISCHER,M.NOBLE,J.A.ENDICOTT,C.PEPPER,S.WANG JRNL TITL SUBSTITUTED 4-(THIAZOL-5-YL)-2-(PHENYLAMINO)PYRIMIDINES ARE JRNL TITL 2 HIGHLY ACTIVE CDK9 INHIBITORS: SYNTHESIS, X-RAY CRYSTAL JRNL TITL 3 STRUCTURE, SAR AND ANTI-CANCER ACTIVITIES. JRNL REF J.MED.CHEM. V. 56 640 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23301767 JRNL DOI 10.1021/JM301475F REMARK 2 REMARK 2 RESOLUTION. 3.09 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.7.0029 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.09 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 82.63 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 20066 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING + TEST SET) : 0.163 REMARK 3 R VALUE (WORKING SET) : 0.161 REMARK 3 FREE R VALUE : 0.197 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.180 REMARK 3 FREE R VALUE TEST SET COUNT : 1023 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 3.09 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 3.17 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1433 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.67 REMARK 3 BIN R VALUE (WORKING SET) : 0.2860 REMARK 3 BIN FREE R VALUE SET COUNT : 80 REMARK 3 BIN FREE R VALUE : 0.3420 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4591 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 42 REMARK 3 SOLVENT ATOMS : 16 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 90.83 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.46800 REMARK 3 B22 (A**2) : -0.46800 REMARK 3 B33 (A**2) : 1.51900 REMARK 3 B12 (A**2) : -0.46800 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 1.636 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.307 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.220 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 27.464 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.963 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.947 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4738 ; 0.011 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6421 ; 1.433 ; 1.972 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 562 ; 5.385 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 218 ;33.912 ;23.991 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 848 ;16.028 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 31 ;19.781 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 716 ; 0.101 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3529 ; 0.008 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 589 ; 0.262 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 799 ; 0.346 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 28 ; 0.232 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 4738 ; 7.733 ; 6.551 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 1998 ;12.044 ;10.730 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 280 ;16.286 ;20.827 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 12343 ;13.503 ;63.012 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 7 A 327 REMARK 3 ORIGIN FOR THE GROUP (A): 47.4486 -17.8388 -1.4617 REMARK 3 T TENSOR REMARK 3 T11: 0.2095 T22: 0.1233 REMARK 3 T33: 0.1628 T12: -0.0680 REMARK 3 T13: -0.0587 T23: 0.0057 REMARK 3 L TENSOR REMARK 3 L11: 1.7195 L22: 2.2473 REMARK 3 L33: 3.1004 L12: 0.0737 REMARK 3 L13: 0.0206 L23: -0.6109 REMARK 3 S TENSOR REMARK 3 S11: 0.2372 S12: -0.0977 S13: -0.4886 REMARK 3 S21: 0.2646 S22: -0.2319 S23: 0.0087 REMARK 3 S31: 0.5469 S32: 0.0904 S33: -0.0053 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 8 B 259 REMARK 3 ORIGIN FOR THE GROUP (A): 21.5363 3.6576 -20.3435 REMARK 3 T TENSOR REMARK 3 T11: 0.0906 T22: 0.1401 REMARK 3 T33: 0.0598 T12: -0.0112 REMARK 3 T13: -0.0439 T23: -0.0343 REMARK 3 L TENSOR REMARK 3 L11: 3.0359 L22: 2.0447 REMARK 3 L33: 1.0546 L12: -1.2695 REMARK 3 L13: -0.4243 L23: 0.0762 REMARK 3 S TENSOR REMARK 3 S11: -0.0091 S12: -0.0238 S13: 0.2645 REMARK 3 S21: 0.1241 S22: 0.0981 S23: -0.2325 REMARK 3 S31: -0.0537 S32: 0.0505 S33: -0.0890 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK BULK SOLVENT REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 4BCG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 02-OCT-12. REMARK 100 THE DEPOSITION ID IS D_1290054247. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I03 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9763 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20079 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.080 REMARK 200 RESOLUTION RANGE LOW (A) : 86.400 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.8700 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.08 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.25 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : 3.40 REMARK 200 R MERGE FOR SHELL (I) : 0.51000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.510 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: PHENIX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTALS WERE GROWN AT 4C USING 10-16% REMARK 280 PEG 1000, 100MM NAK-PHOSPHATE PH 6.2, 500MM NACL, 4MM TCEP AS REMARK 280 THE PRECIPITANT SOLUTION. THEY WERE SUBSEQUENTLY SOAKED IN THE REMARK 280 PRESENCE OF COMPOUND., TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: H 3 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z REMARK 290 3555 -X+Y,-X,Z REMARK 290 4555 X+2/3,Y+1/3,Z+1/3 REMARK 290 5555 -Y+2/3,X-Y+1/3,Z+1/3 REMARK 290 6555 -X+Y+2/3,-X+1/3,Z+1/3 REMARK 290 7555 X+1/3,Y+2/3,Z+2/3 REMARK 290 8555 -Y+1/3,X-Y+2/3,Z+2/3 REMARK 290 9555 -X+Y+1/3,-X+2/3,Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 86.40000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 49.88306 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 32.96000 REMARK 290 SMTRY1 5 -0.500000 -0.866025 0.000000 86.40000 REMARK 290 SMTRY2 5 0.866025 -0.500000 0.000000 49.88306 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 32.96000 REMARK 290 SMTRY1 6 -0.500000 0.866025 0.000000 86.40000 REMARK 290 SMTRY2 6 -0.866025 -0.500000 0.000000 49.88306 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 32.96000 REMARK 290 SMTRY1 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 99.76613 REMARK 290 SMTRY3 7 0.000000 0.000000 1.000000 65.92000 REMARK 290 SMTRY1 8 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 8 0.866025 -0.500000 0.000000 99.76613 REMARK 290 SMTRY3 8 0.000000 0.000000 1.000000 65.92000 REMARK 290 SMTRY1 9 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 9 -0.866025 -0.500000 0.000000 99.76613 REMARK 290 SMTRY3 9 0.000000 0.000000 1.000000 65.92000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2350 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 27720 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -13.5 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 465 PRO A 1 REMARK 465 ALA A 2 REMARK 465 LYS A 3 REMARK 465 GLN A 4 REMARK 465 TYR A 5 REMARK 465 ASP A 6 REMARK 465 ALA A 89 REMARK 465 SER A 90 REMARK 465 PRO A 91 REMARK 465 TYR A 92 REMARK 465 ASN A 93 REMARK 465 ARG A 94 REMARK 465 CYS A 95 REMARK 465 LYS A 96 REMARK 465 LEU A 328 REMARK 465 SER A 329 REMARK 465 THR A 330 REMARK 465 GLY B 0 REMARK 465 PRO B 1 REMARK 465 GLU B 2 REMARK 465 GLY B 3 REMARK 465 GLU B 4 REMARK 465 ARG B 5 REMARK 465 LYS B 6 REMARK 465 ASN B 7 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O ASN A 255 OD1 ASN A 258 2.04 REMARK 500 O ARG B 25 N GLY B 28 2.11 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 9 129.64 -36.67 REMARK 500 CYS A 10 57.76 -156.15 REMARK 500 PHE A 30 -133.84 54.01 REMARK 500 ASN A 54 77.71 60.33 REMARK 500 ARG A 86 -166.63 -100.11 REMARK 500 THR A 87 -47.67 -132.00 REMARK 500 ASP A 149 44.32 -149.75 REMARK 500 ASP A 167 78.23 58.32 REMARK 500 ALA A 177 -125.32 54.31 REMARK 500 ASN A 179 10.32 82.22 REMARK 500 ARG A 184 66.89 -116.05 REMARK 500 VAL A 190 132.15 81.87 REMARK 500 ASP A 205 69.56 -112.89 REMARK 500 SER A 226 140.12 -170.39 REMARK 500 GLN A 230 66.80 -100.03 REMARK 500 ASN A 255 -4.55 86.29 REMARK 500 ASP A 257 4.26 -60.24 REMARK 500 GLU A 260 3.82 -64.18 REMARK 500 ARG A 284 -59.23 78.39 REMARK 500 ARG B 26 -45.54 -22.13 REMARK 500 TYR B 37 -48.04 -28.11 REMARK 500 PHE B 146 18.81 59.97 REMARK 500 SER B 215 162.61 -45.26 REMARK 500 ASN B 250 -7.71 72.86 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE T3C A 1328 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 1329 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 1260 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PF6 RELATED DB: PDB REMARK 900 IN SILICO STRUCTURE OF PROTEIN KINASE 9 REMARK 900 RELATED ID: 4BCF RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCH RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCI RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCJ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCK RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCN RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCO RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCP RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 4BCQ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2 -AMINO-4- REMARK 900 HETEROARYL-PYRIMIDINE INHIBITOR DBREF 4BCG A 2 330 UNP P50750 CDK9_HUMAN 2 330 DBREF 4BCG B 2 259 UNP O60563 CCNT1_HUMAN 2 259 SEQADV 4BCG GLY A 0 UNP P50750 EXPRESSION TAG SEQADV 4BCG PRO A 1 UNP P50750 EXPRESSION TAG SEQADV 4BCG GLY B 0 UNP O60563 EXPRESSION TAG SEQADV 4BCG PRO B 1 UNP O60563 EXPRESSION TAG SEQADV 4BCG ARG B 77 UNP O60563 GLN 77 ENGINEERED MUTATION SEQADV 4BCG GLY B 96 UNP O60563 GLU 96 ENGINEERED MUTATION SEQADV 4BCG LEU B 241 UNP O60563 PHE 241 ENGINEERED MUTATION SEQRES 1 A 331 GLY PRO ALA LYS GLN TYR ASP SER VAL GLU CYS PRO PHE SEQRES 2 A 331 CYS ASP GLU VAL SER LYS TYR GLU LYS LEU ALA LYS ILE SEQRES 3 A 331 GLY GLN GLY THR PHE GLY GLU VAL PHE LYS ALA ARG HIS SEQRES 4 A 331 ARG LYS THR GLY GLN LYS VAL ALA LEU LYS LYS VAL LEU SEQRES 5 A 331 MET GLU ASN GLU LYS GLU GLY PHE PRO ILE THR ALA LEU SEQRES 6 A 331 ARG GLU ILE LYS ILE LEU GLN LEU LEU LYS HIS GLU ASN SEQRES 7 A 331 VAL VAL ASN LEU ILE GLU ILE CYS ARG THR LYS ALA SER SEQRES 8 A 331 PRO TYR ASN ARG CYS LYS GLY SER ILE TYR LEU VAL PHE SEQRES 9 A 331 ASP PHE CYS GLU HIS ASP LEU ALA GLY LEU LEU SER ASN SEQRES 10 A 331 VAL LEU VAL LYS PHE THR LEU SER GLU ILE LYS ARG VAL SEQRES 11 A 331 MET GLN MET LEU LEU ASN GLY LEU TYR TYR ILE HIS ARG SEQRES 12 A 331 ASN LYS ILE LEU HIS ARG ASP MET LYS ALA ALA ASN VAL SEQRES 13 A 331 LEU ILE THR ARG ASP GLY VAL LEU LYS LEU ALA ASP PHE SEQRES 14 A 331 GLY LEU ALA ARG ALA PHE SER LEU ALA LYS ASN SER GLN SEQRES 15 A 331 PRO ASN ARG TYR TPO ASN ARG VAL VAL THR LEU TRP TYR SEQRES 16 A 331 ARG PRO PRO GLU LEU LEU LEU GLY GLU ARG ASP TYR GLY SEQRES 17 A 331 PRO PRO ILE ASP LEU TRP GLY ALA GLY CYS ILE MET ALA SEQRES 18 A 331 GLU MET TRP THR ARG SER PRO ILE MET GLN GLY ASN THR SEQRES 19 A 331 GLU GLN HIS GLN LEU ALA LEU ILE SER GLN LEU CYS GLY SEQRES 20 A 331 SER ILE THR PRO GLU VAL TRP PRO ASN VAL ASP ASN TYR SEQRES 21 A 331 GLU LEU TYR GLU LYS LEU GLU LEU VAL LYS GLY GLN LYS SEQRES 22 A 331 ARG LYS VAL LYS ASP ARG LEU LYS ALA TYR VAL ARG ASP SEQRES 23 A 331 PRO TYR ALA LEU ASP LEU ILE ASP LYS LEU LEU VAL LEU SEQRES 24 A 331 ASP PRO ALA GLN ARG ILE ASP SER ASP ASP ALA LEU ASN SEQRES 25 A 331 HIS ASP PHE PHE TRP SER ASP PRO MET PRO SER ASP LEU SEQRES 26 A 331 LYS GLY MET LEU SER THR SEQRES 1 B 260 GLY PRO GLU GLY GLU ARG LYS ASN ASN ASN LYS ARG TRP SEQRES 2 B 260 TYR PHE THR ARG GLU GLN LEU GLU ASN SER PRO SER ARG SEQRES 3 B 260 ARG PHE GLY VAL ASP PRO ASP LYS GLU LEU SER TYR ARG SEQRES 4 B 260 GLN GLN ALA ALA ASN LEU LEU GLN ASP MET GLY GLN ARG SEQRES 5 B 260 LEU ASN VAL SER GLN LEU THR ILE ASN THR ALA ILE VAL SEQRES 6 B 260 TYR MET HIS ARG PHE TYR MET ILE GLN SER PHE THR ARG SEQRES 7 B 260 PHE PRO GLY ASN SER VAL ALA PRO ALA ALA LEU PHE LEU SEQRES 8 B 260 ALA ALA LYS VAL GLU GLY GLN PRO LYS LYS LEU GLU HIS SEQRES 9 B 260 VAL ILE LYS VAL ALA HIS THR CYS LEU HIS PRO GLN GLU SEQRES 10 B 260 SER LEU PRO ASP THR ARG SER GLU ALA TYR LEU GLN GLN SEQRES 11 B 260 VAL GLN ASP LEU VAL ILE LEU GLU SER ILE ILE LEU GLN SEQRES 12 B 260 THR LEU GLY PHE GLU LEU THR ILE ASP HIS PRO HIS THR SEQRES 13 B 260 HIS VAL VAL LYS CYS THR GLN LEU VAL ARG ALA SER LYS SEQRES 14 B 260 ASP LEU ALA GLN THR SER TYR PHE MET ALA THR ASN SER SEQRES 15 B 260 LEU HIS LEU THR THR PHE SER LEU GLN TYR THR PRO PRO SEQRES 16 B 260 VAL VAL ALA CYS VAL CYS ILE HIS LEU ALA CYS LYS TRP SEQRES 17 B 260 SER ASN TRP GLU ILE PRO VAL SER THR ASP GLY LYS HIS SEQRES 18 B 260 TRP TRP GLU TYR VAL ASP ALA THR VAL THR LEU GLU LEU SEQRES 19 B 260 LEU ASP GLU LEU THR HIS GLU LEU LEU GLN ILE LEU GLU SEQRES 20 B 260 LYS THR PRO ASN ARG LEU LYS ARG ILE TRP ASN TRP ARG MODRES 4BCG TPO A 186 THR PHOSPHOTHREONINE HET TPO A 186 11 HET T3C A1328 30 HET GOL A1329 6 HET GOL B1260 6 HETNAM TPO PHOSPHOTHREONINE HETNAM T3C 2-[[3-(1,4-DIAZEPAN-1-YL)PHENYL]AMINO]-4-[4-METHYL-2- HETNAM 2 T3C (METHYLAMINO)-1,3-THIAZOL-5-YL]PYRIMIDINE-5- HETNAM 3 T3C CARBONITRILE HETNAM GOL GLYCEROL HETSYN TPO PHOSPHONOTHREONINE HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 1 TPO C4 H10 N O6 P FORMUL 3 T3C C21 H24 N8 S FORMUL 4 GOL 2(C3 H8 O3) FORMUL 6 HOH *16(H2 O) HELIX 1 1 PRO A 60 LEU A 73 1 14 HELIX 2 2 LEU A 110 SER A 115 1 6 HELIX 3 3 THR A 122 ASN A 143 1 22 HELIX 4 4 LYS A 151 ALA A 153 5 3 HELIX 5 5 THR A 191 ARG A 195 5 5 HELIX 6 6 PRO A 196 LEU A 201 1 6 HELIX 7 7 PRO A 208 ARG A 225 1 18 HELIX 8 8 THR A 233 GLY A 246 1 14 HELIX 9 9 ASN A 255 TYR A 259 5 5 HELIX 10 10 LEU A 261 GLU A 266 1 6 HELIX 11 11 LYS A 274 ARG A 284 1 11 HELIX 12 12 ASP A 285 LEU A 296 1 12 HELIX 13 13 ASP A 305 HIS A 312 1 8 HELIX 14 14 ASP A 313 TRP A 316 5 4 HELIX 15 15 THR B 15 ASN B 21 1 7 HELIX 16 16 SER B 22 PHE B 27 1 6 HELIX 17 17 ASP B 30 LEU B 52 1 23 HELIX 18 18 SER B 55 TYR B 70 1 16 HELIX 19 19 PRO B 79 GLU B 95 1 17 HELIX 20 20 LYS B 100 HIS B 113 1 14 HELIX 21 21 SER B 123 LEU B 144 1 22 HELIX 22 22 HIS B 152 VAL B 164 1 13 HELIX 23 23 SER B 167 THR B 185 1 19 HELIX 24 24 THR B 186 GLN B 190 5 5 HELIX 25 25 THR B 192 ASN B 209 1 18 HELIX 26 26 HIS B 220 ASP B 226 1 7 HELIX 27 27 THR B 230 THR B 248 1 19 HELIX 28 28 ASN B 250 TRP B 256 1 7 SHEET 1 AA 5 TYR A 19 LYS A 24 0 SHEET 2 AA 5 VAL A 33 HIS A 38 -1 O LYS A 35 N LEU A 22 SHEET 3 AA 5 LYS A 44 LYS A 49 -1 O VAL A 45 N ALA A 36 SHEET 4 AA 5 TYR A 100 ASP A 104 -1 O LEU A 101 N LYS A 48 SHEET 5 AA 5 LEU A 81 CYS A 85 -1 N ILE A 82 O VAL A 102 SHEET 1 AB 3 HIS A 108 ASP A 109 0 SHEET 2 AB 3 VAL A 155 ILE A 157 -1 O ILE A 157 N HIS A 108 SHEET 3 AB 3 LEU A 163 LEU A 165 -1 O LYS A 164 N LEU A 156 SHEET 1 AC 2 ILE A 145 LEU A 146 0 SHEET 2 AC 2 ARG A 172 ALA A 173 -1 O ARG A 172 N LEU A 146 LINK N TPO A 186 C TYR A 185 1555 1555 1.33 LINK C TPO A 186 N ASN A 187 1555 1555 1.34 CISPEP 1 ASN A 54 GLU A 55 0 22.73 CISPEP 2 ALA A 177 LYS A 178 0 2.45 CISPEP 3 ASP A 318 PRO A 319 0 -7.80 SITE 1 AC1 13 ILE A 25 THR A 29 VAL A 33 VAL A 79 SITE 2 AC1 13 PHE A 103 ASP A 104 PHE A 105 CYS A 106 SITE 3 AC1 13 GLU A 107 ASP A 109 ASN A 154 LEU A 156 SITE 4 AC1 13 ASP A 167 SITE 1 AC2 5 ILE A 61 LYS A 68 LYS B 93 VAL B 94 SITE 2 AC2 5 GLY B 96 SITE 1 AC3 4 TYR B 37 PRO B 79 GLY B 80 ASN B 81 CRYST1 172.800 172.800 98.880 90.00 90.00 120.00 H 3 9 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005787 0.003341 0.000000 0.00000 SCALE2 0.000000 0.006682 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010113 0.00000